価格表

在庫・価格 : 2024年06月23日 19時31分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-TOR/mTOR (pSer2448), Phosphorylated, Rabbit-Poly
データシート
NB600-607 NOVノバス バイオロジカルス
Novus biologicals, LLC
0.1 mg ¥127,000
(未発注)
追加

在庫・価格 : 2024年06月23日 19時31分 現在

Anti-TOR/mTOR (pSer2448), Phosphorylated, Rabbit-Poly

  • 商品コード:NB600-607
  • メーカー:NOV
  • 包装:0.1mg
  • 価格: ¥127,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Gupta M et al. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood 2009 May;113(21):5206-16
Gupta M et al
2009/01/01
PubMed
2 Lisi L et al. The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation 2011;8(1):1
Lisi L et al
2011/01/01
Species: Rat, Applications: WB PubMed
3 Lisi L et al. The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. J Neuroinflammation 2014;11:125
Lisi L et al
2014/01/01
Species: Rat, Applications: WB PubMed
4 Lisi L et al. Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells. ASN Neuro 2014;6(3):171-83
Lisi L et al
2014/01/01
Species: Rat, Applications: WB PubMed
5 Zhou X et al. Eriocalyxin B, a novel autophagy inducer, exerts anti-tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer. Biochem. Pharmacol. 2017 10;142:58-70
Zhou X et al
2017/01/01
Species: Human, Applications: IHC-P PubMed
6 Serafin V et al. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric <i>ETV6-RUNX1</i> B-Acute Lymphoblastic Leukemia Patients. Int J Mol Sci 2019 Dec;20(24)
Serafin V et al
2019/01/01
PubMed
  • No.: 1
  • 文献情報:
    Gupta M et al. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood 2009 May;113(21):5206-16
    Gupta M et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Lisi L et al. The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation 2011;8(1):1
    Lisi L et al
    2011/01/01
  • 備考:
    Species: Rat, Applications: WB
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Lisi L et al. The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. J Neuroinflammation 2014;11:125
    Lisi L et al
    2014/01/01
  • 備考:
    Species: Rat, Applications: WB
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Lisi L et al. Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells. ASN Neuro 2014;6(3):171-83
    Lisi L et al
    2014/01/01
  • 備考:
    Species: Rat, Applications: WB
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Zhou X et al. Eriocalyxin B, a novel autophagy inducer, exerts anti-tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer. Biochem. Pharmacol. 2017 10;142:58-70
    Zhou X et al
    2017/01/01
  • 備考:
    Species: Human, Applications: IHC-P
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Serafin V et al. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric <i>ETV6-RUNX1</i> B-Acute Lymphoblastic Leukemia Patients. Int J Mol Sci 2019 Dec;20(24)
    Serafin V et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed